"Nov. 19, 2012 -- Unemployment and a history of job loss may raise the risk for heart attack, a new study suggests.
The risk of heart attack may be highest during the first year of unemployment. And the more jobs a person loses, the hi"...
Although most bleeding associated with the use of Angiomax (bivalirudin) in PCI/PTCA occurs at the site of arterial puncture, hemorrhage can occur at any site. An unexplained fall in blood pressure or hematocrit should lead to serious consideration of a hemorrhagic event and cessation of Angiomax administration [see ADVERSE REACTIONS]. Angiomax (bivalirudin) should be used with caution in patients with disease states associated with an increased risk of bleeding.
Coronary Artery Brachytherapy
An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of Angiomax (bivalirudin) in gamma brachytherapy.
If a decision is made to use Angiomax (bivalirudin) during brachytherapy procedures, maintain meticulous catheter technique, with frequent aspiration and flushing, paying special attention to minimizing conditions of stasis within the catheter or vessels [see ADVERSE REACTIONS].
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term studies in animals have been performed to evaluate the carcinogenic potential of Angiomax (bivalirudin) . Angiomax (bivalirudin) displayed no genotoxic potential in the in vitro bacterial cell reverse mutation assay (Ames test), the in vitro Chinese hamster ovary cell forward gene mutation test (CHO/HGPRT), the in vitro human lymphocyte chromosomal aberration assay, the in vitro rat hepatocyte unscheduled DNA synthesis (UDS) assay, and the in vivo rat micronucleus assay. Fertility and general reproductive performance in rats were unaffected by subcutaneous doses of Angiomax (bivalirudin) up to 150 mg/kg/day, about 1.6 times the dose on a body surface area basis (mg/m²) of a 50 kg person given the maximum recommended dose of 15 mg/kg/day.
Use In Specific Populations
Pregnancy Category B
Reproductive studies have been performed in rats at subcutaneous doses up to 150 mg/kg/day, (1.6 times the maximum recommended human dose based on body surface area) and rabbits at subcutaneous doses up to 150 mg/kg/day (3.2 times the maximum recommended human dose based on body surface area). These studies revealed no evidence of impaired fertility or harm to the fetus attributable to Angiomax (bivalirudin) . There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Angiomax (bivalirudin) is intended for use with aspirin [see INDICATIONS AND USAGE]. Because of possible adverse effects on the neonate and the potential for increased maternal bleeding, particularly during the third trimester, Angiomax (bivalirudin) and aspirin should be used together during pregnancy only if clearly needed.
It is not known whether bivalirudin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Angiomax (bivalirudin) is administered to a nursing woman.
The safety and effectiveness of Angiomax (bivalirudin) in pediatric patients have not been established.
In studies of patients undergoing PCI, 44% were ≥ 65 years of age and 12% of patients were ≥ 75 years old. Elderly patients experienced more bleeding events than younger patients. Patients treated with Angiomax (bivalirudin) experienced fewer bleeding events in each age stratum, compared to heparin.
The disposition of Angiomax (bivalirudin) was studied in PTCA patients with mild, moderate and severe renal impairment. The clearance of Angiomax (bivalirudin) was reduced approximately 20% in patients with moderate and severe renal impairment and was reduced approximately 80% in dialysis-dependent patients. [see CLINICAL PHARMACOLOGY].
Last reviewed on RxList: 7/20/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Angiomax Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.